Las Vegas, NV -- (SBWIRE) -- 01/06/2014 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Rentech, Inc.(NASDAQ:RTK), Pan American Silver Corp. (USA)(NASDAQ:PAAS), PDL BioPharma Inc.(NASDAQ:PDLI), 58.com Inc(NYSE:WUBA)
Rentech, Inc.(NASDAQ:RTK) was a volume gainer of 1.72 million shares and the average volume of the stock remained 2.09 million shares. The stock opened the session at $1.73 and finished at the end of the day at $1.79 and the stock escalated 2.87%.The market capitalization of the stock remained 406.00 million. Rentech, Inc., through its subsidiaries, engages in the manufacture and sale of natural-gas based nitrogen fertilizer products in the United States and Brazil. Its products include ammonium sulfate, sulfuric acid, and ammonium thiosulfate used in the production of corn, soybeans, potatoes, cotton, canola, alfalfa, and wheat.
For How Long RTK will fight for Profitability? Read This Trend Analysis report
In the preceding trading session, Pan American Silver Corp. (USA)(NASDAQ:PAAS) exchanged 1.71 million shares and the average volume remained 2.12 million shares. The stock closed the session at $11.84 with the drop of -1.00%. Pan American Silver Corp. engages in the exploration, development, and operation of silver producing properties and assets. It produces and sells silver, gold, copper, lead, and zinc. Pan American Silver Corp. was incorporated in 1979 and is headquartered in Vancouver, Canada.
Why Should Investors Buy PAAS After the Recent Fall? Just Go Here and Find Out
PDL BioPharma Inc.(NASDAQ:PDLI) enhanced 0.82% and its closing price was $8.61. The volume of the stock was 1.68 million shares and the average volume remained 2.73 million shares. The market capitalization of the stock remained 1.21 billion. The beta of the stock remained 0.60. PDL BioPharma, Inc. engages in intellectual property asset management and patent portfolio and related assets investment activities. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases, as well as other medical conditions.
Why Should Investors Buy PDLI After The Recent Gain? Just Go Here and Find Out
58.com Inc(NYSE:WUBA) exchanged 1.67 million shares in the previous trading session, and its average trading remained 705,612.00 shares. WUBA dropped -3.37% and it closed the trading at $36.71. The market capitalization of the stock remained 201.90 million. Beijing 58 Information and Technology Co., Ltd. owns and operates an on-line classified advertisement services Web Site under the name 58.com. The Web Site helps individuals and SMEs to broadcast and search information relating to job opportunities, housing, dating, community events, services, and trading of second hand products.
Has WUBA Found The Bottom and Ready To Move Up? Find Out Here
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)